Pharma Breathes Sigh Of Relief Over Post-Brexit Trade Deal
Despite Cautious Welcome, Industry Warns That The Story Is Far From Over
The devil will be in the detail but the UK/EU industry's first reaction to the last-minute post-Brexit trade deal is one of relief.
You may also be interested in...
The trade deal agreed by the EU and the UK may have brought some relief to the life sciences sector in that it averts the chaos that would have followed failure to reach a deal, but it contains little that will have a direct impact on the regulation of medicines.
October and November 2020 were bad months for companies seeking to have their planned EU filings fast-tracked through the centralized drug review system at the European Medicines Agency.
The Israel-based, NASDAQ-listed biotech tells Scrip that if the oral SK2 selective inhibitor succeeds in a Phase II/III study, it would be "very comfortable" taking opaganib all the way to market on its own.